Types and Management of Benign and Malignant Salivary Gland Tumors
Benign Salivary Gland Tumors
Common Types
The most frequent benign salivary gland tumors are pleomorphic adenoma and Warthin tumor, predominantly affecting the parotid gland 1. Other benign entities include:
- Pleomorphic adenoma - Most common benign tumor with potential for recurrence and malignant transformation 2
- Warthin tumor - Second most common benign tumor
- Basal cell adenoma
- Myoepithelioma
- Oncocytoma
- Cystadenoma
- Canalicular adenoma
- Sialadenoma papilliferum
- Ductal papillomas
- Sebaceous adenoma
- Lymphadenoma
Newly recognized entities in the 5th WHO Classification (2024) include intercalated duct adenoma/hyperplasia, striated duct adenoma, sclerosing polycystic adenoma, and keratocystoma 3, 4.
Management of Benign Tumors
Surgical excision remains the primary treatment for benign salivary gland tumors, though watchful waiting may be appropriate in selected cases 1. The key surgical principle is complete tumor removal while preserving adjacent nerves (particularly the facial nerve) and healthy salivary gland tissue 1.
Important caveat: Pleomorphic adenoma requires particular attention due to its risk of recurrence and potential for malignant transformation if incompletely excised 2.
Malignant Salivary Gland Tumors
Common Malignant Types
Approximately one-third of salivary gland tumors are malignant 2. Key histologic types include:
- Mucoepidermoid carcinoma - Most common malignancy
- Adenoid cystic carcinoma (ACC)
- Acinic cell carcinoma
- Salivary duct carcinoma (SDC) - High rate of nodal involvement (>20%)
- Adenocarcinoma not otherwise specified
- Carcinoma ex pleomorphic adenoma
- Polymorphous adenocarcinoma (including cribriform adenocarcinoma subtype)
- Secretory carcinoma
- Hyalinizing clear cell carcinoma
Newly recognized malignant entities (WHO 2024) include microsecretory adenocarcinoma and sclerosing microcystic adenocarcinoma 4.
Surgical Management Algorithm for Malignant Tumors
Intraoperative Decision-Making
Frozen section analysis should be utilized during surgery with 98.5% sensitivity and 99% specificity for detecting malignant parotid tumors 5. However, surgeons must refrain from making decisions resulting in major harm (such as facial nerve sacrifice) based solely on indeterminate frozen section results 5.
Extent of Parotidectomy Based on Tumor Characteristics
For T1-T2 Low-Grade Tumors:
Partial superficial parotidectomy is sufficient for appropriately located superficial T1 or T2 low-grade salivary gland cancers 5. The evidence supporting this approach includes:
- 100% locoregional control in T1-2N0 low/intermediate-grade mucoepidermoid carcinoma with margins ≤2 mm 5
- 90.6% 5-year disease-free survival with margins between 1-5 mm 5
- Additional excision of uninvolved parotid parenchyma is unnecessary 5
Rationale: Low-grade tumors behave similarly to benign neoplasms with low metastatic spread rates, making extensive resection unnecessary when complete excision is achieved 5.
For T3-T4 or High-Grade Tumors:
At least superficial parotidectomy should be performed with consideration of total or subtotal parotidectomy due to risk of intraparotid nodal metastases 5. The surgical approach must account for:
- Primary tumor removal
- Adjacent at-risk parotid lymph nodes
- Balance between oncologic control and facial nerve preservation
Critical point: While 22% of patients may have deep lobe involvement, no data demonstrate that more aggressive surgery improves survival or locoregional control when adjuvant therapy is used 5. Given that adjuvant radiation is recommended for advanced/high-grade cancers, superficial parotidectomy with removal of additional parotid tissue (when safe for the facial nerve) is advised 5.
Facial Nerve Management
Facial nerve branches should be resected only when this allows complete margin clearance OR when the nerve is grossly infiltrated or encased by malignancy 5. Key evidence:
- No statistically significant difference in disease-free survival between total parotidectomy (nerve-sparing) versus radical parotidectomy (nerve sacrifice) 5
- In adenoid cystic carcinoma, facial nerve resection did not improve local control over nerve preservation 5
- Clear surgical margins are more important than nerve sacrifice for local control 5
The functional and quality-of-life implications of facial nerve sacrifice outweigh uncertain oncologic benefits 5.
Neck Management
For Clinically Negative Neck (cN0):
Elective neck treatment should be offered over observation for T3-T4 tumors and high-grade malignancies 5. Supporting evidence:
- High-grade histologies (SDC, adenocarcinoma NOS, carcinoma ex pleomorphic adenoma, mucoepidermoid carcinoma) have >20% rate of nodal involvement 5
- Predictors of lymph node metastases: major nerve invasion, histologic grade, lymphovascular invasion, extracapsular invasion 5
- Elective neck irradiation resulted in 100% regional control versus 20% neck recurrence with observation 5
For operative elective neck management of parotid malignancies, ipsilateral selective neck dissection should include levels 2-4 5.
For Clinically Positive Neck (cN1):
Ipsilateral neck dissection of involved and at-risk levels should be performed, potentially extending to levels 1-5 5.
Adjuvant Therapy
Adjuvant external radiation is indicated for malignant tumors with high-risk features 6:
- Close (≤5 mm) or positive margins
- Perineural invasion
- Lymphatic and/or vascular invasion
- Lymph node involvement
- High-grade histology
Surgical margins should be ≥5 mm for malignant tumors, though the facial nerve should be preserved when not infiltrated 6.
Systemic Therapy Considerations
For recurrent/metastatic disease:
- Polychemotherapy (cisplatin-based) provides 25% response rate in adenoid cystic carcinoma and should be used when disease is overtly progressing 6
- Targeted therapies (anti-EGFR, antiangiogenic agents, tyrosine kinase inhibitors) are under investigation 6
- Anti-androgen therapy may be indicated for highly selected patients 7
Key Molecular Alterations
Gene fusions are tightly tumor-type specific and valuable for diagnostically challenging cases 4. Recurrent molecular alterations now define several entities including mucoepidermoid carcinoma, adenoid cystic carcinoma, secretory carcinoma, polymorphous adenocarcinoma, and others 4.